

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CIRTEK HOLDINGS LIMITED

常達控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock code: 1433)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Reference is made to the annual report of Cirtek Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2020 (the “**Annual Report**”) published on 29 April 2021 and the announcement (the “**Announcement**”) of the Company dated 11 March 2020 in relation to the allotment results of the global offering (“**Global Offering**”) of the shares (“**Shares**”) of the Company. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Annual Report.

SHARE OPTION SCHEME

The board of directors of the Company (the “**Board**”) wishes to clarify an inadvertent clerical error in page 122 of the Annual Report (note 30 to the financial statements) regarding the vesting and exercise period of the share options granted:

50% of the 2,000,000 share options granted shall be exercisable from 31 December 2021 (instead of 1 January 2022) to 14 September 2025, and the remaining 50% shall be exercisable from 31 December 2023 (instead of 1 January 2024) to 14 September 2025.

In addition, the Board wishes to provide to the Shareholders and the potential investors with the following additional information in relation to the Share Option Scheme:

The 2,000,000 share options granted are valid for 5 years from the date of grant (up to 14 September 2025). The said share options granted will be lapsed automatically if not exercised within the validity period. The closing price of the Shares before the date of grant of the share options under the Scheme was HK\$0.059. As at the date of the Annual Report, 200,000,000 Shares are available for issue under the Scheme, representing approximately 10.0% of the total number of Shares in issue (i.e. 2,000,000,000 Shares as at the date of the Annual Report). Pursuant to the Scheme and Rule 17.03(5) of the Listing Rules, the Shares under an option granted under the Scheme must be taken up within 10 years from the date of grant of the option.

NET PROCEEDS FROM THE LISTING

As stated in the Announcement, the net proceeds from the Global Offering to be received by the Company, after deducting the underwriting fees and commissions and other estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$74.9 million. As stated in the Annual Report, the net proceeds from the Listing, net of underwriting commission in respect of the Global Offering and other relevant expenses, amounted to approximately HK\$69.9 million. The difference of the estimated and actual net proceeds amounts as disclosed in the Announcement and the Annual Report was due to an increase in the listing expenses in the amount of HK\$5 million.

The above information does not affect other information contained in the Annual Report and save as disclosed above, all other information in the Annual Report remains unchanged.

By order of the Board
Cirtek Holdings Limited
CHAN Sing Ming Barry
Chairman and Executive Director

Hong Kong, 21 October 2021

As at the date of this announcement, the Board comprises Mr. Chan Sing Ming Barry, Ms. Law Miu Lan and Mr. Chan Tsz Fung being executive directors; and Mr. Lam Chor Ki Dick, Mr. Lee Tak Cheong and Ms. Luk Mei Yan being independent non-executive directors.